As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management

As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast.

Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.

Medicine

Health & Fitness

OncologyEducation, in partnership with Dr. Shaqil Kassam, is proud to present the MedOncNow podcast. Hosted by Dr. Kassam, MedOncNow offers critical insights on hot topics in medical oncology. From emerging therapies to new standards of care, MedOncNow features discussions with leading oncology experts who share relevant, practical information you can incorporate into your practice.

Share TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

Sign up to save your podcasts

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley

TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley